SCHEMBL1307965

SCHEMBL1307965

CCOc1ccc(C(=O)Nc2ccc(Br)cc2C(=O)O)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C2 P52895 3/20 0.77
AKR1C1 Q04828 3/20 0.77
MEN1 O00255 3/20 0.69
KMT2A Q03164 3/20 0.69
NPC1 O15118 1/20 0.69
RAB9A P51151 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
PLK1 P53350 3/20 0.58
KCNK2 O95069 1/20 0.57
KCNK10 P57789 1/20 0.57
MAPT P10636 5/20 0.56
AKR1C4 P17516 1/20 0.56
AKR1C3 P42330 1/20 0.56
GPR35 Q9HC97 1/20 0.56
TSHR P16473 2/20 0.54
MAPK1 P28482 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC8 Q9BY41 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
KDM4E B2RXH2 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6346862 0.90 AKR1C2 (0.80) AKR1C2AKR1C1MEN1KMT2ANPC1
SCHEMBL6350022 0.90 AKR1C2 (0.72) AKR1C2AKR1C1MEN1KMT2ANPC1
SCHEMBL6348181 0.89 AKR1C2 (0.64) AKR1C2AKR1C1MEN1KMT2ANPC1
SCHEMBL6353181 0.88 AKR1C2 (0.77) AKR1C2AKR1C1MEN1KMT2ANPC1
SCHEMBL6353212 0.88 AKR1C2 (0.66) AKR1C2AKR1C1MEN1KMT2ANPC1
SCHEMBL6350825 0.87 AKR1C2 (1.00) AKR1C2AKR1C1MEN1KMT2ANPC1
SCHEMBL6349411 0.87 AKR1C2 (0.59) AKR1C2AKR1C1MEN1KMT2ANPC1
SCHEMBL6349385 0.86 AKR1C2 (0.71) AKR1C2AKR1C1MEN1KMT2ANPC1
SCHEMBL1309321 0.86 MEN1 (0.70) AKR1C2AKR1C1MEN1KMT2ANPC1
SCHEMBL6349859 0.86 MAPT (0.76) AKR1C2AKR1C1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2009-02-12 US claimed
US-20050113450-A1 Antibacterial agents PHARMACIA & UPJOHN COMPANY 2005-05-26 US claimed
WO-2004022525-A1 AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2004-03-18 WO claimed
WO-2004018414-A2 ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 WO claimed
US-8053454-B2 Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2011-11-08 US disclosed
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2009-02-12 US disclosed
WO-2004022525-A1 AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 PIM1, PIM3, PIM2 AKR1C2 2289/4885AKR1C1 1435/4885MEN1 2312/4885
US-20050113450-A1 Antibacterial agents CLPP, SPOUT1, SAMHD1 AKR1C2 3012/4885AKR1C1 2615/4885MEN1 3274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.